Mangoceuticals, Inc. Stock-Based Compensation
Mangoceuticals, Inc. (MGRX) reported Stock-Based Compensation of $1.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $12.42K, a 75.64% decline year-over-year.
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.09M, a 2038.36% increase year-over-year.
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was -$33.47K, a 165.66% decline year-over-year.
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.10M, a 911.23% increase year-over-year.
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.17M, a 369.79% increase from fiscal 2024.
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $248.68K, a 60.18% decline from fiscal 2023.
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $624.46K, a 166.76% increase from fiscal 2022.
- Mangoceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $234.09K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.10M 10-Q · filed 2026-08-13 | $1.07M derived: sum of 3 quarters · filed 2026-08-13 | $2.17M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $1.09M 10-Q · filed 2026-05-19 | $1.06M derived: sum of 2 quarters · filed 2026-05-19 | $2.16M derived: sum of 3 quarters · filed 2026-05-19 | $2.21M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$33.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $1.07M derived: sum of 2 quarters · filed 2026-04-01 | $1.12M derived: sum of 3 quarters · filed 2026-08-13 | $1.17M 10-K · filed 2026-04-01 | ||
| 2025-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.15M derived: sum of 2 quarters · filed 2026-08-13 | $1.20M 10-Q · filed 2025-11-14 | $1.25M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $50.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $101.96K 10-Q · filed 2026-08-13 | $152.94K derived: sum of 3 quarters · filed 2026-08-13 | $261.69K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $50.98K 10-Q · filed 2026-05-19 | $101.96K derived: sum of 2 quarters · filed 2026-05-19 | $210.72K derived: sum of 3 quarters · filed 2026-05-19 | $261.70K derived: sum of 4 quarters · filed 2026-05-19 | ||
| 2024-12-31 | $50.98K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $159.74K derived: sum of 2 quarters · filed 2026-04-01 | $210.72K derived: sum of 3 quarters · filed 2026-04-01 | $248.68K 10-K · filed 2026-04-01 | ||
| 2024-09-30 | $108.76K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-11-14 | $159.74K derived: sum of 2 quarters · filed 2025-11-14 | $197.70K 10-Q · filed 2025-11-14 | $626.78K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $50.98K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2025-11-14 | $88.94K 10-Q/A · filed 2025-11-14 | $518.02K derived: sum of 3 quarters · filed 2025-11-14 | $584.87K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $37.97K 10-Q · filed 2025-05-15 | $467.04K derived: sum of 2 quarters · filed 2025-05-15 | $533.89K derived: sum of 3 quarters · filed 2025-05-15 | $598.16K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $429.08K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $495.92K derived: sum of 2 quarters · filed 2025-03-20 | $560.19K derived: sum of 3 quarters · filed 2025-03-20 | $624.46K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $66.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $131.11K derived: sum of 2 quarters · filed 2024-11-14 | $195.38K 10-Q · filed 2024-11-14 | $259.65K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $64.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $128.54K 10-Q · filed 2024-08-14 | $192.81K derived: sum of 3 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $64.27K 10-Q · filed 2024-05-15 | $186.43K 10-Q · filed 2023-05-10 | $128.54K derived: sum of 2 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $64.27K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $234.09K 10-K · filed 2024-04-01 | $82.27K 10-Q · filed 2023-05-10 | |||
| 2022-09-30 | $169.82K 10-Q · filed 2023-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |